Case Studies: Chapter 4 — Dosing and Long-term Treatment Patient Case: Eva This chapter reviews the case of a patient with tardive dyskinesia (TD) as a result of treatment for major …

Watch patient story videos discussing their Tardive Dyskinesia (TD) and experiences with AUSTEDO XR® extended release tablets. See safety info and boxed warning.

AUSTEDO XR® Case Study: A Patient’s Journey With Teva cordially invites you to a presentation and discussion entitled: Case Study: A Patient's Journey With AUSTEDO XR® Moderated by: …

Nov 2, 2024 · Teva also presented findings on real-world patient experience with AUSTEDO XR from a non-interventional, prospective, cross-sectional survey, which included adults with TD …

The dose of AUSTEDO XR and AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. Table 1 displays the recommended …

Nov 12, 2024 · The survey examined patient-reported ease of use, effectiveness, and satisfaction. In this interim analysis of data from 131 respondents, results revealed that 87% reported …

Potential Positives Over 94% of surveyed patients with tardive dyskinesia reported movement improvement after receiving treatment with AUSTEDO XR. High patient satisfaction was …

Charts and graphs with adverse reactions, outcomes, patient ages and sex, number of reports by year, and more for AUSTEDO XR (DEUTETRABENAZINE) as reported in 856 cases to the …

Apr 19, 2024 · About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) …

2.1 Dosing Information The dose of AUSTEDO XR and AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. Table 1 …